Avanos Medical, Inc. (AVNS)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$24.99+0.04%
Close 2026-07-24 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AVNS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 715.9 | 701.2 | 687.8 | 673.3 | 684.1 | 587.0 | 714.8 | 697.6 | 652.3 | 611.6 | 566.2 | 509.0 | 1,672.1 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 611.6 | 566.2 | 509.0 | 1,672.1 |
| Cost of Revenues | 357.6 | 347.3 | 306.5 | 293.6 | 289.9 | 287.8 | 343.9 | 295.4 | 261.4 | — | — | — | — |
| Gross Profit | 358.3 | 353.9 | 381.3 | 379.7 | 394.2 | 299.2 | 370.9 | 402.2 | 390.9 | 336.9 | 297.2 | 257.8 | 548.6 |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | 317.6 | 315.6 | 318.5 | 335.0 | 326.5 | 285.3 | 332.6 | 399.1 | 340.4 | 321.7 | 346.2 | 349.7 | 424.5 |
| R&D Expenses | 23.1 | 23.3 | 26.2 | 27.2 | 29.2 | 30.6 | 34.9 | 37.7 | 41.8 | 38.2 | 38.4 | 27.6 | 33.6 |
| Other Operating Expenses, Total | (3.6) | 0.4 | 3.9 | (13.3) | (3.0) | (22.3) | (51.9) | (21.1) | (8.2) | (20.1) | (19.7) | (16.2) | 3.8 |
| Operating Income | (63.0) | (61.6) | (396.2) | 4.2 | 35.5 | (39.0) | (48.5) | (55.7) | 0.5 | (43.1) | (107.1) | (135.7) | 94.3 |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 7.8 | 12.2 | 15.0 | 10.0 | 3.3 | 15.6 | 15.0 | 26.4 | 31.6 | 32.7 | 33.1 | 6.0 |
| Interest & Investment Income | 1.9 | 3.2 | 5.1 | 2.9 | 1.2 | 0.2 | 1.2 | 6.7 | 7.8 | 2.5 | 0.6 | 0.3 | 2.9 |
| Net Interest Expenses | — | — | — | 12.1 | 8.8 | 3.1 | 14.4 | 8.3 | 18.6 | 29.1 | 32.1 | 32.8 | 3.1 |
| Asset Writedown | — | — | — | — | — | 7.9 | 21.5 | — | — | — | 0.0 | 0.0 | 41.9 |
| EBT, Incl. Unusual Items | (68.3) | (66.2) | (403.3) | (7.9) | 26.7 | (42.1) | (62.9) | (64.0) | (18.1) | (72.2) | (139.2) | (168.5) | 91.2 |
| Income Tax Expense | 6.1 | 6.7 | (17.0) | 2.0 | 5.2 | (11.2) | (33.9) | (18.1) | (9.6) | (40.1) | (55.9) | (67.3) | 64.1 |
| Net Income | |||||||||||||
| Net Income | (74.4) | (72.9) | (392.1) | (61.8) | 50.5 | 6.3 | (29.0) | (45.9) | 57.5 | 79.3 | 39.8 | (426.3) | 27.1 |
| Per Share | |||||||||||||
| Basic EPS | (1.60) | (1.57) | (8.53) | (1.32) | 1.08 | 0.13 | (0.61) | (0.96) | 1.22 | 1.69 | 0.85 | (9.15) | 0.58 |
| Diluted EPS | (1.57) | (1.57) | (8.53) | (1.32) | 1.07 | 0.13 | (0.61) | (0.96) | 1.22 | 1.69 | 0.85 | (9.15) | 0.58 |
| Revenue per Share | 15.07 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 46.5 | 46.3 | 46.0 | 46.6 | 46.9 | 48.1 | 47.8 | 47.6 | 47.2 | 46.8 | 46.6 | 46.6 | 46.5 |
| Diluted Weighted Avg Shares | 47.5 | 46.3 | 46.0 | 46.6 | 47.3 | 48.6 | 47.8 | 47.6 | 47.2 | 46.8 | 46.6 | 46.6 | 46.5 |
| Supplemental | |||||||||||||
| EBITDA | — | (22.7) | (350.7) | 50.3 | 83.2 | (0.7) | (5.6) | (18.8) | 34.0 | 16.4 | (41.9) | (70.3) | 179.7 |
| EBIT | (63.0) | (61.6) | (396.2) | 4.2 | 35.5 | (39.0) | (48.5) | (55.7) | 0.5 | (43.1) | (107.1) | (135.7) | 94.3 |
| Effective Tax Rate | -8.9% | — | — | -25.3% | 19.5% | 26.6% | 53.9% | 28.3% | 53.0% | 55.5% | 40.2% | 39.9% | 70.3% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.